ClinicalTrials.gg
WithdrawnNCT06555263Updated Aug 22, 2025

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 2 interventional study of Luveltamab tazevibulin in Lung Cancer, Lung Cancer Metastatic and Lung Cancer, Nonsmall Cell, sponsored by Sutro Biopharma, Inc.. Withdrawn at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sutro Biopharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Terminated Early

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
2,926th of 3,001
0 · median 56
Started
2024
with 157 others
Phase 2
1,080 of 3,374
121 open now
Registered
3,063rd of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 2,926th largest by enrollment of the 3,001 interventional ones that give a count, is one of 158 that started in 2024, is one of 1,080 in phase 2, and was the 3,063rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

Read the detailed description

This is a multicenter, open-label study. The study is designed to assess the preliminary efficacy and safety of luveltamab tazevibulin, an anti-FOLR1 antibody drug conjugate (ADC) in previously treated subjects with advanced or metastatic NSCLC that expresses FOLR1.

Subjects will receive luveltamab tazevibulin administered intravenously every 3 weeks until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.

03

Conditions studied

  • Lung Cancer
  • Lung Cancer Metastatic
  • Lung Cancer, Nonsmall Cell
  • Lung Cancer Non-Small Cell Stage IIIB
  • Lung Cancer Non-small Cell Stage IV
  • Lung Cancer, Non-small Cell

Browse trials for

Keywords

  • FOLR1
  • folate receptor alpha
  • FolRα
  • FRα
  • antibody drug conjugate
  • ADC
  • Luveltamab tazevibulin
  • STRO-002
  • Luvelta
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Sutro Biopharma, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV.
  • Age ≥ 18 years
  • performance status 0 to 1.
  • Received at least 2 but no more than 4 for advanced NSCLC
  • Disease progression during or following the most recent systemic anti-cancer therapy.
  • Positive FOLR1 expression per central testing
  • At least 1 measurable target lesion per 1.1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
  • Untreated central nervous system
  • Ongoing therapy, except for treated , per criterion above.
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
  • Pre-existing ocular disorders, severe or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  • Previous solid organ transplantation
  • Concurrent participation in another therapeutic treatment trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Luveltamab tazevibulin

    4.3 mg/kg q3w Eligible subjects with stable disease (SD) may escalate to 5.2 mg/kg q3w after Cycle 4, with Sponsor approval.

    Drug: Luveltamab tazevibulin

Interventions

  • Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.

    Also known as: STRO-002, luvelta

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Best response of complete response (CR) or partial response (PR) per RECIST 1.1

    Time frame: up to 24 months

Secondary outcomes

  1. Duration of Response (DOR) per Investigator's assessment.

    Confirmed CR or PR from the first documented response to the date of documented disease progression or death.

    Time frame: up to 24 months

  2. Progression Free Survival (PFS) by RECIST v1.1 per Investigator's assessment.

    Time between the date of first dose and the first date of documented progression or death

    Time frame: up to 24 months

  3. Incidence and severity of adverse events and clinical laboratory abnormalities

    Incidence and severity of adverse events (AEs) and clinical laboratory abnormalities.

    Time frame: up to 24 months

  4. ADC concentration

    To evaluate the PK of luveltamab tazevibulin

    Time frame: up to 24 months

  5. Total antibody concentration

    To evaluate the PK of luveltamab tazevibulin

    Time frame: up to 24 months

  6. Cytotoxic warhead concentration

    To evaluate the PK of luveltamab tazevibulin

    Time frame: up to 24 months

08

Study locations

7 sites
  • UC San Diego Health - Moores Cancer Center
    La Jolla, California 92037, United States
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20057, United States
  • Florida Cancer Specialists & Research Institute (FCS)
    Lake Mary, Florida 32746, United States
  • Tampa General Hospital - Cancer Center of South Florida
    Tampa, Florida 33606, United States
  • HealthPartners Frauenshuh Cancer Center
    Saint Louis Park, Minnesota 55426, United States
  • HealthPartners Cancer Center at Regions Hospital
    Saint Paul, Minnesota 55101, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in May 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 15, 2024
StartActual
Aug 21, 2024
Primary completionActual
May 1, 2025
CompletionActual
May 1, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06555263
Lead sponsor
Sutro Biopharma, Inc.
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Aug 21, 2024
Primary completion
May 1, 2025
Completion
May 1, 2025
Last update
Aug 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luveltamab tazevibulin

Start the discussion